Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel after 3 courses of docetaxel in metastatic castration-resistant prostate cancer
jRCTs031220683Recruiting
- Start
- May 2023
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cabazitaxel in prostate cancer (PCa). Primary endpoint: Incidence of peripheral neuropathy during treatment period. Started May 2023; status: recruiting.
02
Drugs
cabazitaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs031220683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220683.